A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.

Autor: Adjei AA; Roswell Park Cancer Institute, Buffalo, New York. alex.adjei@roswellpark.org., Richards DA; The US Oncology Network, The Woodlands, Texas. Texas Oncology-Tyler, Houston, Texas., El-Khoueiry A; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California., Braiteh F; The US Oncology Network, The Woodlands, Texas. Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada., Becerra CH; The US Oncology Network, The Woodlands, Texas. Baylor Sammons Cancer Center, Houston, Texas., Stephenson JJ Jr; The US Oncology Network, The Woodlands, Texas. Institute of Translational Oncology Research, Houston, Texas., Hezel AF; The US Oncology Network, The Woodlands, Texas. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York., Sherman M; University of Toronto and University Health Network, Toronto, Canada., Garbo L; The US Oncology Network, The Woodlands, Texas. New York Oncology Hematology, Albany, New York., Leffingwell DP; Ardea Biosciences, Inc., San Diego, California., Iverson C; Ardea Biosciences, Inc., San Diego, California., Miner JN; The US Oncology Network, The Woodlands, Texas. Ardea Biosciences, Inc., San Diego, California., Shen Z; Ardea Biosciences, Inc., San Diego, California., Yeh LT; Ardea Biosciences, Inc., San Diego, California., Gunawan S; Ardea Biosciences, Inc., San Diego, California., Wilson DM; Ardea Biosciences, Inc., San Diego, California., Manhard KJ; Ardea Biosciences, Inc., San Diego, California., Rajagopalan P; Bayer HealthCare Pharmaceuticals, Whippany, New Jersey., Krissel H; Bayer Pharma AG, Berlin, Germany., Clendeninn NJ; Ardea Biosciences, Inc., San Diego, California.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2016 May 15; Vol. 22 (10), pp. 2368-76. Date of Electronic Publication: 2015 Dec 07.

Transglutaminases are oncogenic biomarkers in human cancers and therapeutic targeting of TGM2 blocks chemoresistance and macrophage infiltration in pancreatic cancer.

Autor: Zhang, Shan¹ (AUTHOR), Yao, Hong-Fei² (AUTHOR), Li, Hui¹ (AUTHOR), Su, Tong³ (AUTHOR), Jiang, Shu-Heng¹ (AUTHOR), Wang, Hao⁴ (AUTHOR), Zhang, Zhi-Gang¹ (AUTHOR) zzhang@shsci.org, Dong, Fang-Yuan⁵ (AUTHOR) dongfangyuan06@163.com, Yang, Qin⁶ (AUTHOR) yangqin200954@163.com, Yang, Xiao-Mei¹ (AUTHOR) xmyang@shsci.org

Publikováno v: Cellular Oncology (2211-3428). Oct2023, Vol. 46 Issue 5, p1473-1492. 20p.

Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.

Autor: Weekes CD; University of Colorado Cancer Center, Aurora, Colorado 80045, USA., Von Hoff DD, Adjei AA, Leffingwell DP, Eckhardt SG, Gore L, Lewis KD, Weiss GJ, Ramanathan RK, Dy GK, Ma WW, Sheedy B, Iverson C, Miner JN, Shen Z, Yeh LT, Dubowy RL, Jeffers M, Rajagopalan P, Clendeninn NJ

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2013 Mar 01; Vol. 19 (5), pp. 1232-43. Date of Electronic Publication: 2013 Feb 22.

Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies.

Autor: Barteselli, Giulio, Goodman, Grant R., Patel, Yogesh, Caro, Ivor, Xue, Cloris, McCallum, Samuel

Publikováno v: Drug Safety; Dec2022, Vol. 45 Issue 12, p1491-1499, 9p

Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.

Autor: Ramanathan, Ramesh K., Von Hoff, Daniel D., Eskens, Ferry, Blumenschein, George, Richards, Donald, Genvresse, Isabelle, Reschke, Susanne, Granvil, Camille, Skubala, Adam, Peña, Carol, Mross, Klaus, Blumenschein, George Jr

Publikováno v: Targeted Oncology; Apr2020, Vol. 15 Issue 2, p163-174, 12p